A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro.
about
Diverse molecular targets for therapeutic strategies in Alzheimer's diseaseDye-binding assays for evaluation of the effects of small molecule inhibitors on amyloid (aβ) self-assemblyProfile of gantenerumab and its potential in the treatment of Alzheimer's diseaseCurcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant α-SynucleinAlpha-helix targeting reduces amyloid-beta peptide toxicity.Discovery of amyloid-beta aggregation inhibitors using an engineered assay for intracellular protein folding and solubility.Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's Aβ peptide and reduce its cytotoxicity.Anti-amyloidogenic properties of some phenolic compoundsProtection against β-amyloid-induced synaptic and memory impairments via altering β-amyloid assembly by bis(heptyl)-cognitinDiscovery and structure activity relationship of small molecule inhibitors of toxic β-amyloid-42 fibril formationInvolvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's disease.Small molecule inhibitors of Abeta assembly.Role of phosphodiesterase 5 in synaptic plasticity and memorySmall molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease.Computational insights into the development of novel therapeutic strategies for Alzheimer's disease.Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connectionsTargeting synaptic dysfunction in Alzheimer's disease therapy.Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010 - 2012).Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.Perspectives on Inhibiting β-Amyloid Aggregation through Structure-Based Drug Design.Inhibition of amyloid oligomerization into different supramolecular architectures by small molecules: mechanistic insights and design rules.The flavonoid derivative 2-(4' Benzyloxyphenyl)-3-hydroxy-chromen-4-one protects against Aβ42-induced neurodegeneration in transgenic Drosophila: insights from in silico and in vivo studies.Keampferol-3-O-rhamnoside abrogates amyloid beta toxicity by modulating monomers and remodeling oligomers and fibrils to non-toxic aggregatesAβ oligomer toxicity inhibitor protects memory in models of synaptic toxicity."Clicked" sugar-curcumin conjugate: modulator of amyloid-β and tau peptide aggregation at ultralow concentrations.Effect of phenolic compounds against Aβ aggregation and Aβ-induced toxicity in transgenic C. elegans.A Ligand-Based NMR Screening Approach for the Identification and Characterization of Inhibitors and Promoters of Amyloid Peptide Aggregation.Detection, inhibition and disintegration of amyloid fibrils: the role of optical probes and macrocyclic receptors.Targeted control of kinetics of beta-amyloid self-association by surface tension-modifying peptides.Aminopyrimidine Class Aggregation Inhibitor Effectively Blocks Aβ-Fibrinogen Interaction and Aβ-Induced Contact System Activation.
P2860
Q26827193-FF6BF075-551C-49F6-9540-8938718C6757Q26852205-AFBE46AA-22BE-47DF-9355-BC1E78D51D1CQ27027675-2BE88450-6362-45A9-9939-0B6090C97CE8Q30410869-80E6E095-F40B-4172-8F87-3ED5D9D84C01Q30488155-E2FDBC97-3E43-48B8-8BF8-FEEF086C5B76Q33403809-D10EB972-D0FF-4928-8541-C5A4D41EB2A3Q33742590-E8EA8EE6-F42F-4A84-86E8-C3A5CF0411ADQ35610830-6C9BEEB4-CFD2-4999-9A68-CF9130C58569Q35868960-A4D3EA78-728D-4E0E-BCDB-B7F49F124FD6Q36298522-0C1E9FD5-49B7-4254-A78D-4DB48AE2E1F8Q36688776-030F341D-9018-4EDC-B3A6-43EA1E54D409Q36911406-0759D974-D3A2-4105-B3C7-3CE958165F51Q37252748-1093422D-DDDA-4C19-8144-10129CFDD227Q37728335-9ABB314A-4A11-4AAF-8345-9191D6587A04Q37855869-A8D7AFB9-EE4E-464E-9697-633BB867F002Q38014513-2D19336C-9340-41D5-97C4-7A4E8FB82963Q38036916-1BDE75F3-A9CD-40DA-A022-7421B666FF4DQ38083082-DD2EDFA5-EB42-4894-A00E-B022D6059C5CQ38299414-54F9601D-E118-4D41-970F-9DD1B6FBF078Q38558352-B360A38B-0022-476B-B8B0-DDCD1E9FC2CAQ38686092-2E2A4289-329B-4432-9C7C-4061F76F63D7Q39215023-02AACE83-47EC-4D49-AB2D-1B3CE2F04269Q39222509-769B9C8C-0E02-4B24-B0E2-87826B56DB9BQ39293031-5C8F2928-62FE-4CD9-8F42-6C4601277C2DQ41992508-F87D5961-BB80-41A9-9D21-B85C8791D358Q46962361-10B6A85C-B5FE-49FC-AE5E-C81403355256Q48103267-9E02C1C8-4EDF-46AD-80D1-886201C83E3CQ48219541-FCDB21B6-2B78-4566-90F6-67F51A15D47FQ48226688-4EEAEA04-F11C-4AE2-BE8C-72DEE66F28DAQ49374917-826A3CFA-E372-410A-8B06-C7BF2EF28941
P2860
A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A novel beta-sheet breaker, RS ...... ng-term potentiation in vitro.
@ast
A novel beta-sheet breaker, RS ...... ng-term potentiation in vitro.
@en
type
label
A novel beta-sheet breaker, RS ...... ng-term potentiation in vitro.
@ast
A novel beta-sheet breaker, RS ...... ng-term potentiation in vitro.
@en
prefLabel
A novel beta-sheet breaker, RS ...... ng-term potentiation in vitro.
@ast
A novel beta-sheet breaker, RS ...... ng-term potentiation in vitro.
@en
P2093
P2860
P356
P1476
A novel beta-sheet breaker, RS ...... ng-term potentiation in vitro.
@en
P2093
Hiroshi Kogen
Isao Kaneko
Kazuo Koyama
Masaki Meguro
Satoko Nishimura
Shinji Marumoto
Takako Murasugi
Tomiichiro Oda
Yasuhiro Nakagami
P2860
P304
P356
10.1038/SJ.BJP.0704911
P407
P577
2002-11-01T00:00:00Z